• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Scholar Rock Holding Corporation

    7/29/24 7:27:50 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SRRK alert in real time by email
    SC 13G/A 1 d768278dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934*

    (Amendment No. 8)

     

     

    Scholar Rock Holding Corporation

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    80706P103

    (CUSIP Number)

    July 25, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐

    Rule 13d-1(b)

     

    ☒

    Rule 13d-1(c)

     

    ☐

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 80706P103       13G

     

    1   

    NAMES OF REPORTING PERSONS

     

    Invus Public Equities, L.P.

    2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐   (b) ☐

     

    3   

    SEC USE ONLY

     

    4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Bermuda

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

    SOLE VOTING POWER

     

    12,834,446

       6   

    SHARED VOTING POWER

     

    0

       7   

    SOLE DISPOSITIVE POWER

     

    12,834,446

       8   

    SHARED DISPOSITIVE POWER

     

    0

    9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    12,834,446

    10   

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    15.8%

    12   

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    PN

     

    2


    CUSIP No. 80706P103       13G

     

    1   

    NAMES OF REPORTING PERSONS

     

    Invus Public Equities Advisors, LLC

    2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐   (b) ☐

     

    3   

    SEC USE ONLY

     

    4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

    SOLE VOTING POWER

     

    12,834,446

       6   

    SHARED VOTING POWER

     

    0

       7   

    SOLE DISPOSITIVE POWER

     

    12,834,446

       8   

    SHARED DISPOSITIVE POWER

     

    0

    9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    12,834,446

    10   

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    15.8%

    12   

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    3


    CUSIP No. 80706P103       13G

     

    1   

    NAMES OF REPORTING PERSONS

     

    Invus Global Management, LLC

    2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐   (b) ☐

     

    3   

    SEC USE ONLY

     

    4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

    SOLE VOTING POWER

     

    12,834,446

       6   

    SHARED VOTING POWER

     

    0

       7   

    SOLE DISPOSITIVE POWER

     

    12,834,446

       8   

    SHARED DISPOSITIVE POWER

     

    0

    9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    12,834,446

    10   

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    15.8%

    12   

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    4


    CUSIP No. 80706P103       13G

     

    1   

    NAMES OF REPORTING PERSONS

     

    Siren, L.L.C.

    2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐   (b) ☐

     

    3   

    SEC USE ONLY

     

    4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

    SOLE VOTING POWER

     

    12,834,446

       6   

    SHARED VOTING POWER

     

    0

       7   

    SOLE DISPOSITIVE POWER

     

    12,834,446

       8   

    SHARED DISPOSITIVE POWER

     

    0

    9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    12,834,446

    10   

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    15.8%

    12   

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    5


    CUSIP No. 80706P103       13G

     

    1   

    NAMES OF REPORTING PERSONS

     

    Raymond Debbane

    2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐   (b) ☐

     

    3   

    SEC USE ONLY

     

    4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Panama

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

    SOLE VOTING POWER

     

    12,834,446

       6   

    SHARED VOTING POWER

     

    0

       7   

    SOLE DISPOSITIVE POWER

     

    12,834,446

       8   

    SHARED DISPOSITIVE POWER

     

    0

    9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    12,834,446

    10   

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    15.8%

    12   

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

    6


    CUSIP No. 80706P103       13G

     

    1   

    NAMES OF REPORTING PERSONS

     

    Artal International S.C.A.

    2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐   (b) ☐

     

    3   

    SEC USE ONLY

     

    4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Luxembourg

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

    SOLE VOTING POWER

     

    0

       6   

    SHARED VOTING POWER

     

    0

       7   

    SOLE DISPOSITIVE POWER

     

    0

       8   

    SHARED DISPOSITIVE POWER

     

    0

    9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10   

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0%

    12   

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    7


    CUSIP No. 80706P103       13G

     

    1   

    NAMES OF REPORTING PERSONS

     

    Artal International Management S.A.

    2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐   (b) ☐

     

    3   

    SEC USE ONLY

     

    4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Luxembourg

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    0

        6   

    SHARED VOTING POWER

     

    0

        7   

    SOLE DISPOSITIVE POWER

     

    0

        8   

    SHARED DISPOSITIVE POWER

     

    0

    9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10   

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0%

    12   

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    8


    CUSIP No. 80706P103       13G

     

    1   

    NAMES OF REPORTING PERSONS

     

    Artal Group S.A.

    2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐   (b) ☐

     

    3   

    SEC USE ONLY

     

    4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Luxembourg

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

    SOLE VOTING POWER

     

    0

       6   

    SHARED VOTING POWER

     

    0

       7   

    SOLE DISPOSITIVE POWER

     

    0

       8   

    SHARED DISPOSITIVE POWER

     

    0

    9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10   

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0%

    12   

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    9


    CUSIP No. 80706P103       13G

     

    1   

    NAMES OF REPORTING PERSONS

     

    Westend S.A.

    2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐   (b) ☐

     

    3   

    SEC USE ONLY

     

    4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Luxembourg

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

    SOLE VOTING POWER

     

    0

       6   

    SHARED VOTING POWER

     

    0

       7   

    SOLE DISPOSITIVE POWER

     

    0

       8   

    SHARED DISPOSITIVE POWER

     

    0

    9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10   

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0%

    12   

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    10


    CUSIP No. 80706P103       13G

     

    1   

    NAMES OF REPORTING PERSONS

     

    Stichting Administratiekantoor Westend

    2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐   (b) ☐

     

    3   

    SEC USE ONLY

     

    4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    The Netherlands

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

    SOLE VOTING POWER

     

    0

       6   

    SHARED VOTING POWER

     

    0

       7   

    SOLE DISPOSITIVE POWER

     

    0

       8   

    SHARED DISPOSITIVE POWER

     

    0

    9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10   

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0%

    12   

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    11


    CUSIP No. 80706P103       13G

     

    1   

    NAMES OF REPORTING PERSONS

     

    Mr. Amaury Wittouck

    2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐   (b) ☐

     

    3   

    SEC USE ONLY

     

    4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Belgium

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

    SOLE VOTING POWER

     

    0

       6   

    SHARED VOTING POWER

     

    0

       7   

    SOLE DISPOSITIVE POWER

     

    0

       8   

    SHARED DISPOSITIVE POWER

     

    0

    9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10   

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0%

    12   

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

    12


    Explanatory Note

    On July 25, 2024, in connection with a reorganization (the “Reorganization”), Global Management replaced the Geneva branch of Artal International as the managing member of Invus PE Advisors (each defined below). Siren (defined below) is the managing member of Global Management and Mr. Raymond Debbane is the managing member of Siren. Accordingly, Artal International, Artal International Management, Artal Group, Westend, the Stichting and Mr. Amaury Wittouck (each defined below and together, the “Artal Parties”) are no longer deemed to beneficially own the Shares directly held by Invus Public Equities (defined below). This Schedule 13G reports beneficial ownership as of July 25, 2024, immediately following the Reorganization, and reflects an exit filing by the Artal Parties and an initial filing on Schedule 13G by Global Management, Siren and Mr. Debbane. See Item 4.

     

    Item 1(a).

    Name of Issuer:

    Scholar Rock Holding Corporation (the “Issuer”)

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    301 Binney Street, 3rd Floor, Cambridge, MA 02142

     

    Item 2(a).

    Name of Person Filing:

     

    Item 2(b).

    Address of Principal Business Office or, if none, Residence:

     

    Item 2(c).

    Citizenship:

    (i) Invus Public Equities, L.P. (“Invus Public Equities”)

    750 Lexington Avenue, 30th Floor, New York, NY 10022

    Citizenship: Bermuda limited partnership

    (ii) Invus Public Equities Advisors, LLC (“Invus PE Advisors”)

    750 Lexington Avenue, 30th Floor, New York, NY 10022

    Citizenship: Delaware limited liability company

    (iii) Invus Global Management, LLC (“Global Management”)

    750 Lexington Avenue, 30th Floor, New York, NY 10022

    Citizenship: Delaware limited liability company

    (iv) Siren, L.L.C. (“Siren”)

    c/o The Invus Group, LLC, 750 Lexington Avenue, 30th Floor, New York, NY 10022

    Citizenship: Delaware limited liability company

    (v) Raymond Debbane

    750 Lexington Avenue, 30th Floor, New York, NY 10022

    Citizenship: Panama

    (vi) Artal International S.C.A. (“Artal International”)

    Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

    Citizenship: Luxembourg limited partnership

    (vii) Artal International Management S.A. (“Artal International Management”)

    Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

    Citizenship: Luxembourg société anonyme

    (viii) Artal Group S.A. (“Artal Group”)

    Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

    Citizenship: Luxembourg société anonyme

     

    13


    (ix) Westend S.A. (“Westend”)

    Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

    Citizenship: Luxembourg société anonyme

    (x) Stichting Administratiekantoor Westend (the “Stichting”)

    Claude Debussylaan, 46, 1082 MD Amsterdam, The Netherlands

    Citizenship: Netherlands foundation

    (xi) Mr. Amaury Wittouck

    Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

    Citizenship: Belgium

    The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.”

     

    Item 2(d).

    Title of Class of Securities:

    Common Stock, par value $0.001 per share (the “Shares”)

     

    Item 2(e).

    CUSIP Number:

    80706P103

     

    Item 3.

    If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing Is a(n):

    This Item 3 is not applicable.

     

    Item 4.

    Ownership.

    (a) Amount beneficially owned:

    As of July 25, 2024, following the Reorganization whereby Global Management became the managing member of Invus PE Advisors, Invus Public Equities directly held 11,259,438 Shares and warrants to purchase up to 1,575,008 Shares, with an exercise price of $7.35 per Share and expiration of December 31, 2025 (the “Warrants”). Invus PE Advisors, as the general partner of Invus Public Equities, controls Invus Public Equities and, accordingly, may be deemed to beneficially own the Shares directly held by Invus Public Equities. Global Management, as the managing member of Invus PE Advisors, controls Invus PE Advisors and, accordingly, may be deemed to beneficially own the Shares that Invus PE Advisors may be deemed to beneficially own. Siren, as the managing member of Global Management, controls Global Management and, accordingly, may be deemed to beneficially own the Shares that Global Management may be deemed to beneficially own. Mr. Raymond Debbane, as the managing member of Siren, controls Siren and, accordingly, may be deemed to beneficially own the Shares that Siren may be deemed to beneficially own.

    (b) Percent of class:

    As of July 25, 2024, following the Reorganization, each of the Reporting Persons may be deemed to be the beneficial owner of the percentage of Shares listed on such Reporting Person’s cover page. Calculations of the percentage of Shares beneficially owned are based on (i) 79,754,065 Shares outstanding as of May 2, 2024 as reported in the Issuer’s Quaterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 7, 2024, plus (ii) 1,575,008 Shares issuable upon exercise of the Warrants.

    (c) Number of shares as to which Invus Public Equities, Invus PE Advisors, Global Management, Siren and Mr. Debbane has:

     

      (i)

    Sole power to vote or to direct the vote:

    12,834,446

     

    14


      (ii)

    Shared power to vote or to direct the vote:

    0

     

      (iii)

    Sole power to dispose or to direct the disposition of:

    12,834,446

     

      (iv)

    Shared power to dispose or to direct the disposition of:

    0

    As of July 25, 2024, following the Reorganization, Artal International, Artal International Management, Artal Group, Westend, the Stichting and Mr. Wittouck are no longer deemed to beneficially own any Shares.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ☐.

    On July 25, 2024, in connection with the Reorganization, Global Management replaced the Geneva branch of Artal International as the managing member of Invus PE Advisors. Accordingly, the Geneva branch of Artal International, Artal International Management, Artal Group, Westend, Stichting and Mr. Wittouck are no longer deemed to beneficially own the Shares directly held by Invus Public Equities and have ceased to be Reporting Persons.

     

    Item 6.

    Ownership of More Than Five Percent on Behalf of Another Person.

    This Item 6 is not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

    This Item 7 is not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    This Item 8 is not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    This Item 9 is not applicable.

     

    Item 10.

    Certification.

    Each of the Reporting Persons hereby makes the following certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    15


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: July 29, 2024

     

    INVUS PUBLIC EQUITIES, L.P.
    By:   INVUS PUBLIC EQUITIES ADVISORS,
    LLC, its general partner
    By:   /s/ Raymond Debbane
    Name:   Raymond Debbane
    Title:   President
    INVUS PUBLIC EQUITIES ADVISORS, LLC
    By:   /s/ Raymond Debbane
    Name:   Raymond Debbane
    Title:   President
    INVUS GLOBAL MANAGEMENT, LLC
    By:   /s/ Raymond Debbane
    Name:   Raymond Debbane
    Title:   President
    SIREN, L.L.C.
    By:   /s/ Raymond Debbane
    Name:   Raymond Debbane
    Title:   President
    MR. RAYMOND DEBBANE
    By:   /s/ Raymond Debbane
    ARTAL INTERNATIONAL S.C.A.
    By:   ARTAL INTERNATIONAL
    MANAGEMENT S.A., its managing partner
    By:   /s/ Anne Goffard
    Name:   Anne Goffard
    Title:   Managing Director


    ARTAL INTERNATIONAL MANAGEMENT S.A.
    By:   /s/ Anne Goffard
    Name:   Anne Goffard
    Title:   Managing Director
    ARTAL GROUP S.A.
    By:   /s/ Anne Goffard
    Name:   Anne Goffard
    Title:   Authorized Person
    WESTEND S.A.
    By:   /s/ Anne Goffard
    Name:   Anne Goffard
    Title:   Managing Director
    STICHTING ADMINISTRATIEKANTOOR WESTEND
    By:   /s/ Amaury Wittouck
    Name:   Amaury Wittouck
    Title:   Sole Member of the Board
    MR. AMAURY WITTOUCK
    /s/ Amaury Wittouck


    EXHIBIT INDEX

     

    Exhibit
    Number

      

    Title

    1.    Joint Filing Agreement
    Get the next $SRRK alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SRRK

    DatePrice TargetRatingAnalyst
    9/15/2025$51.00Outperform
    Leerink Partners
    8/21/2025$50.00Buy
    Jefferies
    7/30/2025$53.00Strong Buy
    Raymond James
    7/17/2025Overweight
    Cantor Fitzgerald
    11/26/2024$40.00 → $50.00Buy
    H.C. Wainwright
    10/7/2024$30.00 → $35.00Buy
    H.C. Wainwright
    3/28/2024$30.00Strong Buy
    Raymond James
    10/25/2023$20.00Hold → Buy
    Jefferies
    More analyst ratings

    $SRRK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Scholar Rock (NASDAQ:SRRK, the "Company")), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that the company granted inducement equity awards covering an aggregate of 120,800 shares of its common stock to 9 newly hired employees, consisting of inducement stock options to purchase an aggregate of 69,029 shares of common stock and inducement restricted stock units, covering an aggregate of 51,771 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the Comp

    9/12/25 4:15:00 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Scholar Rock (NASDAQ:SRRK, the "Company")), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that the company granted inducement equity awards covering an aggregate of 426,250 shares of its common stock to 64 newly hired employees, consisting of inducement stock options to purchase an aggregate of 243,577 shares of common stock and inducement restricted stock units, covering an aggregate of 182,673 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the C

    8/15/25 4:15:00 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment

    First and only muscle-targeted SMA therapy to demonstrate statistically significant, clinically meaningful improvements on the gold-standard HFMSE scale (p=0.019) versus placebo, with consistent benefits across pre-specified subgroups (age, type of SMN-targeted treatment, and SMN-targeted treatment initiation age) and region 30.4% of patients receiving apitegromab had ≥ 3-point improvement in HFMSE versus 12.5% of patients on placebo, despite all study patients receiving chronic, ongoing SMN-targeted treatment 19.6% of patients receiving apitegromab had ≥ 4-point improvement in their HFMSE score versus 6.3% of patients on placebo, despite all study patients receiving chronic, ongoing

    8/14/25 8:00:00 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners initiated coverage on Scholar Rock with a new price target

    Leerink Partners initiated coverage of Scholar Rock with a rating of Outperform and set a new price target of $51.00

    9/15/25 8:09:44 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jefferies resumed coverage on Scholar Rock with a new price target

    Jefferies resumed coverage of Scholar Rock with a rating of Buy and set a new price target of $50.00

    8/21/25 8:19:20 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Raymond James resumed coverage on Scholar Rock with a new price target

    Raymond James resumed coverage of Scholar Rock with a rating of Strong Buy and set a new price target of $53.00

    7/30/25 7:34:00 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Scholar Rock Holding Corporation

    SCHEDULE 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)

    8/14/25 1:07:20 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Scholar Rock Holding Corporation

    10-Q - Scholar Rock Holding Corp (0001727196) (Filer)

    8/6/25 7:16:31 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scholar Rock Holding Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Scholar Rock Holding Corp (0001727196) (Filer)

    8/6/25 7:15:15 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Akkaraju Srinivas bought $15,000,000 worth of shares (2,189,781 units at $6.85) (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    10/18/23 5:46:02 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Samsara Biocapital Gp, Llc bought $15,000,000 worth of shares (2,189,781 units at $6.85) (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    10/18/23 5:44:33 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Invus Public Equities, L.P. bought $15,086,736 worth of shares (2,199,931 units at $6.86) (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    10/16/23 5:46:56 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHRO Parlavecchio Caryn sold $67,880 worth of shares (2,178 units at $31.17), decreasing direct ownership by 1% to 155,464 units (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    8/19/25 4:30:21 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Flier Jeffrey S. sold $445,688 worth of shares (11,136 units at $40.02) (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    7/18/25 4:15:07 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CHIEF SCIENTIFIC OFFICER Qatanani Mo sold $828,898 worth of shares (24,066 units at $34.44), decreasing direct ownership by 17% to 115,495 units (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    7/10/25 9:46:38 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    Leadership Updates

    Live Leadership Updates

    View All

    Scholar Rock Appoints Caryn Parlavecchio as Chief Human Resources Officer

    - Former Vice President and Global HR Head of Oncology and Pharma Development at Novartis brings extensive leadership experience focused on talent, culture, and diversity Scholar Rock (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the appointment of Caryn Parlavecchio as Chief Human Resources Officer. She will join the executive team, bringing more than 20 years of experience as a senior leader and strategic executive in the biotechnology and pharmaceutical industries. This press release features multimedia. View the full release here: https://www.businesswire.co

    8/16/21 4:05:00 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    Financials

    Live finance-specific insights

    View All

    Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Scholar Rock (NASDAQ:SRRK, the "Company")), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that the company granted inducement equity awards covering an aggregate of 120,800 shares of its common stock to 9 newly hired employees, consisting of inducement stock options to purchase an aggregate of 69,029 shares of common stock and inducement restricted stock units, covering an aggregate of 51,771 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the Comp

    9/12/25 4:15:00 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Scholar Rock (NASDAQ:SRRK, the "Company")), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that the company granted inducement equity awards covering an aggregate of 426,250 shares of its common stock to 64 newly hired employees, consisting of inducement stock options to purchase an aggregate of 243,577 shares of common stock and inducement restricted stock units, covering an aggregate of 182,673 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the C

    8/15/25 4:15:00 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment

    First and only muscle-targeted SMA therapy to demonstrate statistically significant, clinically meaningful improvements on the gold-standard HFMSE scale (p=0.019) versus placebo, with consistent benefits across pre-specified subgroups (age, type of SMN-targeted treatment, and SMN-targeted treatment initiation age) and region 30.4% of patients receiving apitegromab had ≥ 3-point improvement in HFMSE versus 12.5% of patients on placebo, despite all study patients receiving chronic, ongoing SMN-targeted treatment 19.6% of patients receiving apitegromab had ≥ 4-point improvement in their HFMSE score versus 6.3% of patients on placebo, despite all study patients receiving chronic, ongoing

    8/14/25 8:00:00 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Scholar Rock Holding Corporation

    SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)

    11/14/24 9:00:58 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Scholar Rock Holding Corporation

    SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)

    11/14/24 7:24:55 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Scholar Rock Holding Corporation

    SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)

    11/14/24 1:22:38 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care